J. N. An, J. P. Lee, H. J. Jeon, D. H. Kim, Y. K. Oh et al., Severe hyperkalemia requiring hospitalization: predictors of mortality, Crit Care, vol.16, p.225, 2012.

P. Rossignol, M. Legrand, M. Kosiborod, S. M. Hollenberg, W. F. Peacock et al., Emergency management of severe hyperkalemia: guideline for best practice and opportunities for the future, Pharmacol Res, vol.113, pp.585-591, 2016.

C. P. Kovesdy, Updates in hyperkalemia: outcomes and therapeutic strategies, Rev Endocr Metab Disord, vol.18, pp.41-47, 2017.

M. Chaitman, D. Dixit, and M. B. Bridgeman, Potassium-binding agents for the clinical management of hyperkalemia, P T, vol.41, pp.43-50, 2016.

D. Lullo, L. Ronco, C. Granata, A. Paoletti, E. Barbera et al., Chronic hyperkalemia in cardiorenal patients: risk factors, diagnosis, and new treatment options, Cardiorenal Med, vol.9, pp.8-21, 2019.

J. Tamargo, R. Caballero, and E. Delpon, New therapeutic approaches for the treatment of hyperkalemia in patients treated with renin-angiotensin-aldosterone system inhibitors, Cardiovasc Drugs Ther, vol.32, pp.99-119, 2018.

P. I. Georgianos and R. Agarwal, Revisiting RAAS blockade in CKD with newer potassium-binding drugs, Kidney Int, vol.93, pp.325-334, 2018.

C. Sarwar, A. A. Bhagat, S. D. Anker, and J. Butler, Role of hyperkalemia in heart failure and the therapeutic use of potassium binders, Handb Exp Pharmacol, vol.243, pp.537-560, 2017.

B. Pitt and G. L. Bakris, New potassium binders for the treatment of hyperkalemia: current data and opportunities for the future, Hypertension, vol.66, pp.731-738, 2015.

M. Epstein and B. Pitt, Recent advances in pharmacological treatments of hyperkalemia: focus on patiromer, Expert Opin Pharmacother, vol.17, pp.1435-1448, 2016.

. Lokelma,

D. E. Wilmington, AstraZeneca Pharmaceuticals LP, 2018.

, Lokelma powder for oral suspension

S. Södertälje, AstraZeneca AB, 2018.

F. Stavros, A. Yang, A. Leon, M. Nuttall, and H. S. Rasmussen, Characterization of structure and function of ZS-9, a K+ selective ion trap, PLoS One, vol.9, p.114686, 2014.

S. R. Ash, B. Singh, P. T. Lavin, F. Stavros, and H. S. Rasmussen, A phase 2 study on the treatment of hyperkalemia in patients with chronic kidney disease suggests that the selective potassium trap, ZS-9, is safe and efficient, Kidney Int, vol.88, pp.404-411, 2015.

M. Kosiborod, H. S. Rasmussen, P. Lavin, W. Y. Qunibi, B. Spinowitz et al., Effect of sodium zirconium cyclosilicate on potassium lowering for 28 days among outpatients with hyperkalemia: the HARMONIZE randomized clinical trial, JAMA, vol.312, pp.2223-2233, 2014.

D. K. Packham, H. S. Rasmussen, P. T. Lavin, M. A. El-shahawy, S. D. Roger et al., Sodium zirconium cyclosilicate in hyperkalemia, N Engl J Med, vol.372, pp.222-231, 2015.

B. S. Spinowitz, S. Fishbane, P. E. Pergola, S. D. Roger, E. V. Lerma et al., Sodium zirconium cyclosilicate in individuals with hyperkalemia: a 12-month phase 3 study, Clin J Am Soc Nephrol, vol.14, pp.798-809, 2019.

M. Epstein, N. L. Reaven, S. E. Funk, K. J. Mcgaughey, N. Oestreicher et al., Evaluation of the treatment gap between clinical guidelines and the utilization of renin-angiotensin-aldosterone system inhibitors, Am J Manag Care, vol.21, pp.212-220, 2015.

K. G. Garlo, D. W. Bates, D. L. Seger, J. M. Fiskio, and D. M. Charytan, Association of changes in creatinine and potassium levels after initiation of renin angiotensin aldosterone system inhibitors with emergency department visits, hospitalizations, and mortality in individuals with chronic kidney disease, JAMA Netw Open, vol.1, p.183874, 2018.

M. R. Weir, Therapeutic potential of newer drugs for treating hyperkalemia, Clin J Am Soc Nephrol, vol.14, pp.787-788, 2019.

, ESC Heart Failure, pp.55-65, 2020.